Post on 01-Feb-2016
description
HIV-1 Assembly in the Endocytic Pathway:
Opportunities for the Identification of Novel Anti-HIV Drug Targets
Éric A. CohenUnité de rétrovirologie humaine
Institut de Recherches Cliniques de Montréal
Symposium on Novel Targets for Drug Development XVI International AIDS Conference
Toronto, August 14, 2006
Gag-Driven HIV-1 Particle Production
HIV-1 Gag
• M domain mediates Gag association to lipid membranes • I domain mediates Gag multimerization
• L domain mediates the last step of viral particle morphogenesis- fission of the viral particle- by interacting with Tsg101, a host cell protein involved in the formation of internal vesicles in MVB.
p6CA (p24) p2 NC p1
M I L
MA(p17)
Mechanism of HIV-1 Budding
HIV-1 Gag co-opts a host cell machinery devoted to the formation of internal vesicles in multivesicular bodies (MVB)
to mediate viral budding
HIV-1 assembles primarily at the plasma membrane in primary T lymphocytes, as well as in many tumor cells lines including Jurkat, HeLa, 293T and Cos cells. HIV-1 buds from intracellular compartments in some cell types, particularly inmacrophages. These intracellular compartments express late endosomal / MVB markers including MHC-II, CD63, Lamp1 and LBPA.
Sites of HIV-1 Assembly and Release
Retroviral assembly
Mechanisms that controls the choice of virus assembly and budding sites remain poorly understood.
What is the route(s) by which Gag reaches its cell surface or MVB steady-state accumulation?
What are the host cell factors that control the choice of HIV buddings sites?
Nucleusp55
p25
p24
Plasma membrane (PM)
Cytoplasm
What is the route by which Gag reaches its PM or MVB steady-state accumulation?
Gag
Late endosome / MVB
Nucleusp55
p25
p24
Plasma membrane (PM)
Cytoplasm
What is the route by which Gag reaches its PM or MVB steady-state accumulation?
Gag
Late endosome / MVB
Nucleusp55
p25
p24
Plasma membrane (PM)
Cytoplasm
What is the route by which Gag reaches its PM or MVB steady-state accumulation?
Gag
Late endosome / MVB
Subcellular Fractionation on a Continuous Iodixanol (Optiprep) Gradient (0-20%)
Disrupt cellsPellet nuclei
PNS
1 2 3 4 5 6 7 8 9 10 11 12 13 14
5%5%
20%20%
Adapted from Ira Mellman(Sheff et al., 1999)
Characterization of Light Density Fractions
Characterization of High Density Fractions
Trafficking of HIV-1 Gag-Associated Products in HEK 293T Cells
p24
Moc
k
0 0.5 2 5 hs
Virus released
Supernatant
Filipin, an Inhibitor of Endocytosis, Prevents Gag Internalization from the PM to MVB
Filipin (4µg/mL)
Transferrin + (clathrin dependent)
Cholera-toxin + (caveolae dependent)
Inhibition (+) Internalization (- )
Effect of Filipin on Transferrin and Cholera-toxin internalization
Internalization of Gag from the PM to MVB Involves an Endocytosis Process that is Clathrin-independent
Chlorpromazin (10 µg/mL)
Transferrin ++ (clathrin dependent)
Cholera-toxin - (caveolae dependent)
Inhibition (+) Internalization (- )
Effect of Chlorpromazin on Transferrin and Cholera-toxin internalization
p55
p25
p24
Route by which Gag reaches its PM or MVB steady-state accumulation in HEK 293T cells
Nucleus
Plasma membrane (PM)
Cytoplasm
Gag
Late endosome / MVB
Clathrinindependentendocytosis
X
X
Questions
– What is the route by which Gag reaches its cell surface or endosomal steady-state accumulation?
– What are the host cell factors that control the site of viral assembly and budding?
MHC-II molecules, which are expressed in macrophages and activated T cells can induce the formation/maturation of endocytic MHC-II-like structures
analogous to MVB in HEK293 cells (Calafat et al., J. Cell Biol., 126: 966-77, 1994).
MHC-II molecules present peptides to CD4+ T cells.
MHC Class II Molecules
MHC-II and HIV
HLA-DR is incorporated into HIV-1 particles (Cantin et al., 1996; Poon et al., 2000; Martin et al., 2005).
HIV-1 Nef protein modulates MHC-II cell surface expression (Stumptner-Cuvelette et al., 2003).
The cytoplasmic tails/transmembrane domain of MHC-II molecules are required for the formation/maturation of these compartments.
To determine whether MHC-II could relocate HIV-1 Gag from the cell surface to intracellular compartments in 293T cells.
Goal
Andrés Finzi Yong Xiao
Gag localization
Diffuse
Punctuate
Gag staining
HLA-DR Induces Gag Accumulation in Intracellular Compartments in 293T Cells
Diffuse
Punctuate
Gag staining
Dose-dependent Gag relocalization by HLA-DR
Gag Accumulates in MVB Upon HLA-DR Expression in HEK 293T Cells
Finzi et al., J. Virol., In Press
HIV-1 Assembles and Buds Within Intracellular Compartments Upon HLA-DR Expression
HIV-1 Assembles at the Plasma Membrane in Absence of HLA-DR
HLA-DR Expression Decreases HIV-1 Release
HIV-1 release(n=8)
Finzi et al., J. Virol., In Press
HxBc2 +/- HLA-DR
0 16 24 48 72Hours post-transfection
IVS 10µMWash cells
Cell lysisand infection of HeLa β-Gal MAGI
assay
-DR
+DR
Mature Virus
Immature Virus
MVB containing mature virus
MVB containing immature virus
Analysis of Cell-Associated Infectivity
HLA-DR Promotes Intracellular Accumulation of Infectious Virus Particles
-Hexosaminidase activityDR- DR+
Finzi et al., J. Virol., In Press
Newly synthesized Gag is primarily targeted to the plasma membrane in HEK 293 T cells. A concomitant direct targeting of newly synthesized Gag to MVB is also detected but represents a minor fraction of total Gag
HIV-1 appears to have adapted to exploit multiple host cell transport pathways to reach and accumulate into MVB
Conclusions (I)
Mature Gag products were found to accumulate into MVB over time by a process of internalization from the cell surface that is independent of clathrin mediated-endocytosis.
HLA-DR expression promotes HIV-1 accumulation to MVB by a process that strictly relies on the cytoplasmic tails of the and chains of classical MHC-II molecules.
Intracellular virions produced in presence of HLA-DR remain stable and infectious, indicating that the stable sequestration of infectious virions within cytoplasmic compartments may represent an additional mechanism of viral persistence in HIV-1 infected individuals.
Overall, these results suggest that MHC-II molecules may represent a cellular determinant promoting HIV-1 accumulation into MVB in MHC-II expressing cells such as macrophages.
Conclusions (II)
Fomation and sequestration of virions into MVB protects HIV from the humoral immune response and is likely to facilitate transfer of virus to target cells.
Given that MVB exocytosis is an essential host cell pathway, effective antiviral agents will need to specifically target interaction of HIV Gag with the endocytic pathway without perturbing the normal host-cell trafficking network.
Implications for Drug Development
A better understanding of MVB exocytosis may suggest ways by which MVB could be prevented from releasing their content or perhaps encouraged to deliver it to lysosomes.
Acknowledgements
Laboratory of HumanRetrovirology, IRCM
Yong Xiao
Alexandre Brunet
Dr. Jacques Thibodeau
Andrés Finzi
Laboratory of Molecular ImmunologyUniversité de Montréal
Alexandre Orthwein
Johanne Mercier
Gag association to membranes (time 0) : SVC21 G2AWT Myr-
Pr55Gag Association to Membranes
% o
f s
ign
al
% o
f s
ign
al
Membranes Cytosol Membranes Cytosol
Inhibition of Transferrin uptake in cell expressing the Dynamin K44A DN mutant
DR- DR+ DR- DR+
Dyn WT Dyn K44A
Gag localization(n=5)
HLA-DR-induced HIV-1 Gag accumulation in MVB is reduced when endocytosis is inhibited
Filipin 4 ug/mL(09-08-06)
Stable HLA-DR Expression in HeLa Cells Induces Gag Accumulation in MVB
MHC-II-Related Molecules Do Not Modify HIV-1 Release Nor Gag Localization
HIV-1 release
HIV-1 Gag localization(n=2)
Finzi et al., J. Virol., In Press
Nucleusp55
p25
p24
Plasma membrane
Cytoplasm
What is the route by which Gag reaches its PM or MVB steady-state accumulation?
Gag
Late endosome / MVB